Literature DB >> 21724319

Epstein-Barr virus and breast cancer: serological study in a high-incidence area of nasopharyngeal carcinoma.

Jian-Rong He1, Lu-Ying Tang, Dan-Dan Yu, Feng-Xi Su, Er-Wei Song, Ying Lin, Shen-Ming Wang, Guan-Chao Lai, Wei-Qing Chen, Ze-Fang Ren.   

Abstract

We investigated IgA and IgG levels against EBV viral capsid antigen (VCA) and nuclear antigen-1 (EBNA-1) in serum of 223 women with breast cancer (BC) and 309 controls in Guangzhou, China. VCA IgA levels were significantly associated with an elevated risk of BC, with adjusted ORs (95%CIs) of 1.70 (1.05-2.76) (seropositivity) and 2.21 (1.11-4.40) (unit increases in OD value). This association was stronger among young, lean, and HER2+ women. The EBNA-1 IgA levels in OD value, but not seropositivity, were associated with an increased risk of BC among ER+, PR+, and HER2+ patients. None of the IgG variables was related to BC. These results suggest the EBV association with BC in an endemic area of nasopharyngeal carcinoma.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21724319     DOI: 10.1016/j.canlet.2011.05.012

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  19 in total

1.  Genetic variants in EBV reactivation-related genes and the risk and survival of breast cancer.

Authors:  Wei Zhang; Zheng-Zheng Zhang; Lu-Ying Tang; Ying Lin; Feng-Xi Su; Xiao-Ming Xie; Xue-Fen Su; Ze-Fang Ren
Journal:  Tumour Biol       Date:  2016-01-05

2.  Potential use of vaccines in the primary prevention of breast cancer in high-risk patients.

Authors:  Matteo Lazzeroni; Davide Serrano
Journal:  Breast Care (Basel)       Date:  2012-08       Impact factor: 2.860

Review 3.  Breast cancer and cytomegalovirus.

Authors:  A K Richardson; L C Walker; B Cox; H Rollag; B A Robinson; H Morrin; J F Pearson; J D Potter; M Paterson; H-M Surcel; E Pukkala; M J Currie
Journal:  Clin Transl Oncol       Date:  2019-06-29       Impact factor: 3.405

4.  Association between weight change and breast cancer prognosis.

Authors:  Yi-Xin Zhang; Zhuo-Zhi Liang; Yun-Qian Li; Ying Lin; Qiang Liu; Xiao-Ming Xie; Lu-Ying Tang; Ze-Fang Ren
Journal:  Breast Cancer Res Treat       Date:  2022-04-18       Impact factor: 4.872

5.  Prognostic value of glutaminase 1 in breast cancer depends on H3K27me3 expression and menopausal status.

Authors:  Meng Zhou; Qian-Xin Chen; Yuan-Zhong Yang; Zhuo-Zhi Liang; Yue-Lin Li; Zi-Yi Huang; Zi-Jin Weng; Xiao-Fang Zhang; Jie-Xia Guan; Lu-Ying Tang; Ze-Fang Ren
Journal:  Virchows Arch       Date:  2021-09-25       Impact factor: 4.064

6.  Time-varying effects of FOXA1 on breast cancer prognosis.

Authors:  Qian-Xin Chen; Yuan-Zhong Yang; Zhuo-Zhi Liang; Jia-Li Chen; Yue-Lin Li; Zi-Yi Huang; Zi-Jin Weng; Xiao-Fang Zhang; Jie-Xia Guan; Lu-Ying Tang; Jing-Ping Yun; Ze-Fang Ren
Journal:  Breast Cancer Res Treat       Date:  2021-02-18       Impact factor: 4.872

7.  Exacerbated metastatic disease in a mouse mammary tumor model following latent gammaherpesvirus infection.

Authors:  Vinita S Chauhan; Daniel A Nelson; Lopamudra Das Roy; Pinku Mukherjee; Kenneth L Bost
Journal:  Infect Agent Cancer       Date:  2012-05-29       Impact factor: 2.965

8.  Joint effects of febrile acute infection and an interferon-γ polymorphism on breast cancer risk.

Authors:  Yi Su; Lu-Ying Tang; Li-Juan Chen; Jian-Rong He; Feng-Xi Su; Ying Lin; Wei-Qing Chen; Xiao-Ming Xie; Ze-Fang Ren
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

Review 9.  Role of viruses in the development of breast cancer.

Authors:  Kenneth Alibek; Ainur Kakpenova; Assel Mussabekova; Marzhan Sypabekova; Nargis Karatayeva
Journal:  Infect Agent Cancer       Date:  2013-09-02       Impact factor: 2.965

10.  An expanded myeloid derived suppressor cell population does not play a role in gammaherpesvirus-exacerbated breast cancer metastases.

Authors:  Daniel A Nelson; Vinita S Chauhan; Melanie D Tolbert; Kenneth L Bost
Journal:  Infect Agent Cancer       Date:  2012-09-04       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.